| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 11, 2008
Revised on June 2, 2008
Accepted on June 11, 2008
From the Experimental Cardiovascular Medicine (A.C., E.P., N.K., A.O., M.M., B.C., P.M., C.E.), and Vascular Biology Divisions (G.B.S.-N.), Bristol Heart Institute, University of Bristol, UK; IRCCS Multimedica Hospital (E.P., G.S.), Milan, Italy; the Department of Molecular Cell Biology and Immunology (A.J.G.H.), VU University Medical Center Amsterdam, Netherlands; Pathology (G.G.), University of Parma, Italy; INSERM Cardiovascular Research Center (A.S.L., C.N.B.), Hôpital Lariboisière, Paris, France; and the Center for Molecular Neurobiology (S.O.Y.), Ohio State University, Columbus.
* To whom correspondence should be addressed. E-mail: Costanza.Emanueli{at}bristol.ac.uk.
Diabetes impairs endothelial function and reparative neovascularization. The p75 receptor of neurotrophins (p75NTR), which is scarcely present in healthy endothelial cells (ECs), becomes strongly expressed by capillary ECs after induction of peripheral ischemia in type-1 diabetic mice. Here, we show that gene transfer-induced p75NTR expression impairs the survival, proliferation, migration, and adhesion capacities of cultured ECs and endothelial progenitor cells (EPCs) and inhibits angiogenesis in vitro. Moreover, intramuscular p75NTR gene delivery impairs neovascularization and blood flow recovery in a mouse model of limb ischemia. These disturbed functions are associated with suppression of signaling mechanisms implicated in EC survival and angiogenesis. In fact, p75NTR depresses the VEGF-A/Akt/eNOS/NO pathway and additionally reduces the mRNA levels of ITGB1 [beta (1) integrin], BIRC5 (survivin), PTTG1 (securin) and VEZF1. Diabetic mice, which typically show impaired postischemic muscular neovascularization and blood perfusion recovery, have these defects corrected by intramuscular gene transfer of a dominant negative mutant form of p75NTR. Collectively, our data newly demonstrate the antiangiogenic action of p75NTR and open new avenues for the therapeutic use of p75NTR inhibition to combat diabetes-induced microvascular liabilities.
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |